MacroGenics has a strong cash position ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments for various ...

MacroGenics has a strong cash position of $240 million ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments ...

MacroGenics has secured $475 million in non-dilutive ... in the development of prostate cancer using our three proprietary technologies, FC engineering, our bispecific DART technology, as well as our ...

Read Our Latest Report on MacroGenics MacroGenics Stock Performance NASDAQ MGNX opened at $1.26 on Thursday. The business’s fifty day moving average is $2.51 and its 200 day moving average is $3 ...

MacroGenics is also investigating different mechanisms of action for mCRPC. The company is running a Phase II trial (NCT05848011) of lorigerlimab, a bispecific, tetravalent PD-1 × CTLA-4 DART ...

We will begin the MacroGenics Fourth Quarter and Full Year ... our bispecific tetravalent DART molecule designed to enable blockade of PD-1 and CTLA-4 with potentially enhanced CTLA-4 blockade ...

MacroGenics has made the final decision to abandon work on one of its more advanced antibody-drug conjugates after taking a look at the latest phase 2 data. The biotech had already paused work on ...

Shares of MacroGenics stock opened at $2.00 on Friday. The company has a market cap of $125.53 million, a PE ratio of -1.27 and a beta of 2.12. MacroGenics has a 52 week low of $1.89 and a 52 week ...